RE:RE:RE:RE:Interesting
Let the Clinical Trial play out. Canaribio is on the hook no matter what. Let's hope Phase 111 succeeds. If it doesn't, Oregovomab would be worthless.
Madiyalakan the CEO of both QPT & OncoQuest Inc. knows he is in no position financially to conduct the Trial. He is gambling that Canaribio may have some success.
Sueing for the IP is not in the cards as things stand. Even if we win, if the stars align, then what? We are caught between a rock and a hard place.
JMO
G1945V